TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9707465

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Salmeterol 100 microg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Salbutamol 200 microg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Salbutamol 400 microg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7977431

Group type: EXPERIMENTAL
Intervention: Patient education and health promotion program (PROPATH)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Control group (received only questionnaires)
Number of subjects: 290
Study: 2607948

Group type: EXPERIMENTAL
Intervention: Cycle training group
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: HCTsub group (70-85% of RM)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: HCTmax group (maximal repetitions possible)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Nonexercising control group
Number of subjects: 32
Study: 29361468

Group type: EXPERIMENTAL
Intervention: Neoadjuvant plus adjuvant dabrafenib and trametinib (8 weeks of neoadjuvant oral dabrafenib 150 mg twice per day and oral trametinib 2 mg per day followed by surgery, then up to 44 weeks of adjuvant dabrafenib plus trametinib starting 1 week after surgery for a total of 52 weeks of treatment)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Standard of care (upfront surgery and consideration for adjuvant therapy)
Number of subjects: 21
Study: 27491453

Group type: EXPERIMENTAL
Intervention: DTL microfiber electrode
Number of subjects: 30

Group type: COMPARATOR
Intervention: Neuroline skin electrode
Number of subjects: 30
Study: 24099723

Group type: EXPERIMENTAL
Intervention: Reduction in dietary trans fat intake
Number of subjects: 400
Study: 22250644

Group type: EXPERIMENTAL
Intervention: Daylight‐mediated PDT with 1½ h exposure
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Daylight‐mediated PDT with 2½ h exposure
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Daylight‐mediated PDT for grade II lesions
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Daylight‐mediated PDT for grade III lesions
Number of subjects: 145
Study: 20471224

Group type: EXPERIMENTAL
Intervention: Cannabis use disorders (CUD)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: CUD subjects
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Multivariate analysis
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-substance abusing subjects
Number of subjects: 100
Study: 18567276

Group type: EXPERIMENTAL
Intervention: AmnioStat‐FLM test (initial analysis)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: AmnioStat‐FLM test (post-freeze-thaw analysis)
Number of subjects: 200
Study: 15839295

Group type: EXPERIMENTAL
Intervention: Nurse-coordinated intervention for 12 weeks by telephone
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Nurse-coordinated intervention
Number of subjects: 25
Study: 12432176

Group type: EXPERIMENTAL
Intervention: High-carbohydrate meal
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High-protein meal
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (High-carbohydrate vs High-protein and High-fat)
Number of subjects: 12
Study: 10857943

Group type: EXPERIMENTAL
Intervention: Octreotide (200-5,000 microg/day subcutaneously)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Conventional diabetes management (control group)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 23
Study: 8931419

Group type: EXPERIMENTAL
Intervention: sucralfate gel 1 g b.i.d. for 14 days
Number of subjects: 107

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 107
Study: 1563120

Group type: EXPERIMENTAL
Intervention: Testosterone treatment (50 mg/m2/day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Testosterone treatment (for boys with initial growth velocity below mean of healthy control group)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Testosterone treatment (for boys with initial growth velocity normal)
Number of subjects: 8
Study: 3161613

Group type: EXPERIMENTAL
Intervention: 300 mg of MPA daily (Group 1)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 600 mg of MPA (Group 2)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 900 mg of MPA (Group 3)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (28 postmenopausal breast cancer patients without treatment)
Number of subjects: 41
Study: 31205120

Group type: EXPERIMENTAL
Intervention: Left high-frequency rTMS
Number of subjects: 25

Group type: COMPARATOR
Intervention: Right high-frequency rTMS
Number of subjects: 25
Study: 30265057

Group type: EXPERIMENTAL
Intervention: Peer Network Counseling‐txt (PNC‐txt)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Assessment only control condition
Number of subjects: 96
Study: 26283739

Group type: EXPERIMENTAL
Intervention: Liraglutide (titrated to a maximum dose of 1.8 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 24742660

Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 1098

Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 1098

Group type: COMPARATOR
Intervention: Sitagliptin 100 mg
Number of subjects: 1098
Study: 21864479

Group type: EXPERIMENTAL
Intervention: Novel paediatric self-inflating bags (NPB)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Conventional paediatric self-inflating bags (CPB)
Number of subjects: 73
Study: 20841339

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy
Number of subjects: 34

Group type: COMPARATOR
Intervention: Usual controlled care
Number of subjects: 34
Study: 17548781

Group type: EXPERIMENTAL
Intervention: Olanzapine (1 to 20 mg/d)
Number of subjects: 1267

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 1267
Study: 16116358

Group type: EXPERIMENTAL
Intervention: Quality improvement intervention including local priority setting, quality improvement plan development, implementation, and monitoring.
Number of subjects: 280
Study: 11699044

Group type: EXPERIMENTAL
Intervention: Highly active antiretroviral therapy (HAART) including AZT or D4T plus 3TC and either IND, NELF, RITV, or SAQ at standard dosage
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group of 42 healthy individuals (28 men and 14 women; 24‐ to 82‐years‐old)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: HAART
Number of subjects: 17
Study: 9156035

Group type: EXPERIMENTAL
Intervention: Hexarelin (2 micrograms/kg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 8
Study: 7956563

Group type: EXPERIMENTAL
Intervention: SVATE (15 cases)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Urokinase (15 cases)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control (22 cases)
Number of subjects: 52
Study: 3675893

Group type: EXPERIMENTAL
Intervention: Paper prosthesis treatment group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no paper prosthesis)
Number of subjects: 60
Study: 2379771

Group type: EXPERIMENTAL
Intervention: Synthetic cholecystokinin‐8 infusion at rates of 21, 42, and 84 pmol/min
Number of subjects: 18

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 18
Study: 4594582

Group type: EXPERIMENTAL
Intervention: Improved method of peroperative intermittent calf compression
Number of subjects: 99
Study: 30573142

Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 1635

Group type: COMPARATOR
Intervention: Health education (Control)
Number of subjects: 1635
Study: 28755971

Group type: EXPERIMENTAL
Intervention: Standardized aqueous extract of H. sabdariffa L. (1000ml)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Standardized aqueous extract of H. sabdariffa L. (1500ml)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Standardized aqueous extract of H. sabdariffa L. (2000ml)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Ferrous sulphate tablet (200mg)
Number of subjects: 130

Group type: COMPARATOR
Intervention: All groups (including control)
Number of subjects: 130
Study: 26068449

Group type: EXPERIMENTAL
Intervention: Group-based interactive self-management education course (2-day duration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study: 23080291

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 20mg/kg/day
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 21798494

Group type: EXPERIMENTAL
Intervention: LVEDP >18 mm Hg
Number of subjects: 2797

Group type: EXPERIMENTAL
Intervention: LVEDP ≥24 mm Hg
Number of subjects: 2797

Group type: EXPERIMENTAL
Intervention: Increased LVEDP
Number of subjects: 2797
Study: 19380385

Group type: EXPERIMENTAL
Intervention: 20-week weight loss programme
Number of subjects: 52
Study: 16763802

Group type: EXPERIMENTAL
Intervention: Preventive home visits with geriatric training for health visitors and general practitioners
Number of subjects: 4034

Group type: COMPARATOR
Intervention: Preventive home visits as usual (control group)
Number of subjects: 4034
Study: 15003079

Group type: EXPERIMENTAL
Intervention: Pindolol, 2.5 mg t.i.d.
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sham augmentation (Control)
Number of subjects: 42
Study: 11716199

Group type: EXPERIMENTAL
Intervention: Budesonide Easyhaler 800 microg day(‐1)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Budesonide Easyhaler 1600 microg day(‐1)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo Easyhaler plus Pulmicort Turbuhaler 800 microg day(‐1)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo Easyhaler plus Pulmicort Turbuhaler 1600 microg day(‐1)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Budesonide Easyhaler and Turbuhaler (both doses)
Number of subjects: 15

Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 15
Study: 9523477

Group type: EXPERIMENTAL
Intervention: HLA-DR surface antigens
Number of subjects: 18

Group type: COMPARATOR
Intervention: CD4, CD8, CD56, CD16 surface antigens
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: CD8 surface antigens
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: CD4 to CD8 ratio
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: T-cells forming active and total rosettes
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: T-cells reaction to theophylline
Number of subjects: 18
Study: 7955272

Group type: EXPERIMENTAL
Intervention: Retrograde warm blood cardioplegia
Number of subjects: 75

Group type: COMPARATOR
Intervention: Antegrade cold crystalloid cardioplegia
Number of subjects: 75
Study: 2440125

Group type: EXPERIMENTAL
Intervention: 24 hour infusion of iloprost
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 19
Study: 29921250

Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham taping (ST)
Number of subjects: 15
Study: 28968227

Group type: EXPERIMENTAL
Intervention: Corrective exercise strategy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional exercises
Number of subjects: 60
Study: 26066651

Group type: EXPERIMENTAL
Intervention: Intensive handwashing promotion (soap and daily handwashing promotion)
Number of subjects: 377

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 377
Study: 23044653

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control (no anesthesia)
Number of subjects: 240
Study: 21278400

Group type: EXPERIMENTAL
Intervention: C-POL intervention
Number of subjects: 3912

Group type: COMPARATOR
Intervention: Standard-care control
Number of subjects: 3912
Study: 19169852

Group type: EXPERIMENTAL
Intervention: Aspirin after endovascular coiling
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Aspirin after neurosurgical clipping
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Magnesium after endovascular coiling
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Magnesium after neurosurgical clipping
Number of subjects: 315
Study: 16267074

Group type: EXPERIMENTAL
Intervention: Effective CPAP therapy
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 31

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 31
Study: 15363431

Group type: EXPERIMENTAL
Intervention: Spinal manipulation only
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Spinal manipulation with physical modalities (PM)
Number of subjects: 72

Group type: COMPARATOR
Intervention: High-velocity low-amplitude spinal manipulation
Number of subjects: 72
Study: 11245648

Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9394693

Group type: EXPERIMENTAL
Intervention: 10 mg Zn/d (zinc supplementation)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 7954566

Group type: COMPARATOR
Intervention: Hypertensive group (HT)
Number of subjects: 90
Study: 2431864

Group type: EXPERIMENTAL
Intervention: 3 mg/kg oral dose of cocaine hydrochloride
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 28177714

Group type: EXPERIMENTAL
Intervention: High-protein intake (HiPROT) at 1.45 g protein/(kg body mass·day) plus 0.72 g branched-chain amino acids per day during BR
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (CON) group receiving 1 g/(kg body mass·day) dietary protein
Number of subjects: 16
Study: 25587171

Group type: EXPERIMENTAL
Intervention: Distractive Auditory Stimuli (DAS)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (no DAS)
Number of subjects: 16
Study: 23263742

Group type: EXPERIMENTAL
Intervention: Casein hydrolysate solution (PRO) - 20 g before, 10 g during, 20 g post-exercise
Number of subjects: 10

Group type: COMPARATOR
Intervention: Non-calorie taste matched placebo (PLA)
Number of subjects: 10
Study: 21511816

Group type: EXPERIMENTAL
Intervention: High-sensitivity C-reactive protein (hsCRP)
Number of subjects: 2102

Group type: EXPERIMENTAL
Intervention: Interleukin-6 (IL-6)
Number of subjects: 2102
Study: 19082328

Group type: EXPERIMENTAL
Intervention: Preoperative and postoperative physiotherapy (G1)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Postoperative physiotherapy only (G2)
Number of subjects: 135
Study: 16877725

Group type: EXPERIMENTAL
Intervention: Epoetin alfa (EPO) 600 units/kg to 900 units/kg, administered intravenously once-weekly for 16 weeks
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo, administered once-weekly for 16 weeks
Number of subjects: 222
Study: 12969089

Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg o.d., amoxicillin 1 g b.d., rabeprazole 20 mg b.d. for 10 days (LAR)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg o.d., tinidazole 500 mg b.d., rabeprazole 20 mg b.d. for 10 days (LTR)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Tetracycline 500 mg q.d.s., metronidazole 500 mg t.d.s., bismuth salt 120 mg q.d.s., rabeprazole 20 mg b.d. for 7 days (7TMBR)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Tetracycline 500 mg q.d.s., metronidazole 500 mg t.d.s., bismuth salt 120 mg q.d.s., rabeprazole 20 mg b.d. for 14 days (14TMBR)
Number of subjects: 280
Study: 10883418

Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 24

Group type: COMPARATOR
Intervention: Fasting treatment
Number of subjects: 24
Study: 9013268

Group type: EXPERIMENTAL
Intervention: Coronary artery disease (CAD) patients
Number of subjects: 77

Group type: COMPARATOR
Intervention: Normal subjects (controls)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Stable angina and acute coronary syndromes (ACS) patients
Number of subjects: 77
Study: 1530028

Group type: EXPERIMENTAL
Intervention: Exogenous human chorionic gonadotropin 5000 IU administered intramuscularly on luteal day 0 (group II)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Exogenous human chorionic gonadotropin 5000 IU administered intramuscularly on luteal day +12 (group V)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Exogenous human chorionic gonadotropin 5000 IU administered intramuscularly on luteal day +4 (group IV)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Exogenous human chorionic gonadotropin 5000 IU administered intramuscularly on luteal day +4 (group IV) and +8 (group III)
Number of subjects: 25

Group type: COMPARATOR
Intervention: No treatment (group I)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Exogenous human chorionic gonadotropin 5000 IU administered intramuscularly on luteal day +8 (group III)
Number of subjects: 25
Study: 6362819

Group type: EXPERIMENTAL
Intervention: Vincristine and Adriamycin (doxorubicin) added to an alkylating agent‐prednisone combination
Number of subjects: 256

Group type: COMPARATOR
Intervention: Two alternating drug combinations
Number of subjects: 256

Group type: COMPARATOR
Intervention: Levamisole during remission maintenance
Number of subjects: 256
Study: 31181357

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of 300,000 IU vitamin D before surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no vitamin D supplementation)
Number of subjects: 60
Study: 30829271

Group type: EXPERIMENTAL
Intervention: Intraoperative ultrasound-guided excision
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional palpation-guided excision
Number of subjects: 60
Study: 26395774

Group type: EXPERIMENTAL
Intervention: Technology-assisted weight loss maintenance intervention (individual face-to-face consultation, mobile internet platform for self-monitoring diet, activity, and weight, automated feedback via mobile phone)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Quarterly newsletters and wirelessly connected scales (control group)
Number of subjects: 288
Study: 23020955

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control (Tab. Glucose)
Number of subjects: 49
Study: 22180399

Group type: EXPERIMENTAL
Intervention: Immediate chemotherapy
Number of subjects: 1442

Group type: COMPARATOR
Intervention: Delayed chemotherapy
Number of subjects: 1442
Study: 19548490

Group type: EXPERIMENTAL
Intervention: Flex Master
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: V-Taper
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 70
Study: 17530982

Group type: EXPERIMENTAL
Intervention: Endurance training (cycling for 20 minutes each day, 3 times per week, for 6 weeks at 70% of VO2max)
Number of subjects: 21
Study: 15155323

Group type: COMPARATOR
Intervention: Droperidol (placebo capsule preoperatively and IV droperidol 0.625 mg before induction)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Dimenhydrinate LA preoperatively and IV placebo before induction
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Combination of dimenhydrinate LA and droperidol
Number of subjects: 141
Study: 11379334

Group type: EXPERIMENTAL
Intervention: amoxicillin, clarithromycin and rabeprazole
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: tinidazole, clarithromycin and ranitidine bismuth citrate
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: tinidazole, clarithromycin and rabeprazole
Number of subjects: 193

Group type: COMPARATOR
Intervention: tinidazole, tetracycline, bismuth and rabeprazole
Number of subjects: 193
Study: 9672795

Group type: EXPERIMENTAL
Intervention: PGTP with adjunctive subconjunctival 5-fluorouracil (5.0 +/- 1.3 injections of 5 mg each, total of 24.8 mg)
Number of subjects: 74

Group type: COMPARATOR
Intervention: PGTP alone (control group)
Number of subjects: 74
Study: 9209607

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg at 50 seconds
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg at 60 seconds
Number of subjects: 30

Group type: COMPARATOR
Intervention: Rocuronium 0.6 mg/kg
Number of subjects: 30
Study: 1662637

Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg once daily for 3 days (Group I)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Azithromycin 250 mg b.i.d. on day 1, followed by 250 mg once daily on days 2 to 5 (Group II)
Number of subjects: 84
Study: 6126900

Group type: EXPERIMENTAL
Intervention: 10 mg diazepam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5 mg diazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31454777

Group type: EXPERIMENTAL
Intervention: Cholecalciferol 100,000 IU every other week for 96 weeks
Number of subjects: 181

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study: 29543838

Group type: EXPERIMENTAL
Intervention: Interpretation bias modification training
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo training
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Both training conditions (Interpretation and Placebo)
Number of subjects: 173
Study: 27122462

Group type: EXPERIMENTAL
Intervention: Intubating laryngeal mask airway (ILMA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Tracheal intubation (Group T)
Number of subjects: 120
Study: 24886676

Group type: EXPERIMENTAL
Intervention: Couple-based psychosexual support intervention (six sessions delivered by trained practitioners)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Couple-based psychosexual support intervention
Number of subjects: 68

Group type: COMPARATOR
Intervention: Standard care (usual follow-up hospital appointments)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Economic analysis of the intervention
Number of subjects: 68
Study: 21988153

Group type: COMPARATOR
Intervention: Providing fabricated feedback indicating above average performance in older women (71 years)
Number of subjects: 2

Group type: COMPARATOR
Intervention: A simple statement suggesting peers usually do well on the task in older women (64 years)
Number of subjects: 2
Study: 20649469

Group type: EXPERIMENTAL
Intervention: Red environment
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Green environment
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Darkness
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 36
Study: 18981627

Group type: EXPERIMENTAL
Intervention: Valsartan/amlodipine combination
Number of subjects: 58

Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 58

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 58